Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07326709 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
A Phase 3 study of Huntington Disease, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 770
- Enrollment target
- 2
- Study locations
NCT07326709 is a Phase 3 study of Huntington Disease that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 770 participants, above the 613-participant average among 35 other Huntington Disease trials with a reported enrollment target (26% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT07326709, a Phase 3 study of Huntington Disease, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 770 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518 from PTC Therapeutics), HTT227 is Novartis code under Novartis sponsorship.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Votoplam (blinded)
Study Locations (2)
District of Columbia
- Georgetown University - Washington D.C.
Quebec
- Novartis Investigative Site - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 770 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2030-04-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07326709
The ClinicalTrials.gov registry entry for NCT07326709 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 770 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 613-participant average among 35 other Huntington Disease trials with a reported enrollment target (26% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Huntington Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07326709 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, Quebec.
Frequently Asked Questions
What is clinical trial NCT07326709 about?
NCT07326709 is a clinical study titled "A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease". The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518 from PTC Therapeutics), HTT227 is ...
What is the current status of trial NCT07326709?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 770 participants. The study started on 2026-06-01. Estimated completion is 2030-04-30.
What conditions does trial NCT07326709 study?
This clinical trial studies the following conditions: Huntington Disease.
What interventions are being tested in trial NCT07326709?
The interventions under investigation include: Placebo (DRUG), Votoplam (blinded) (DRUG).
Who is sponsoring clinical trial NCT07326709?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07326709 being conducted?
This trial has 2 study locations across District of Columbia, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease
COMPLETED · Phase 3
-
A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease
COMPLETED · Phase 3
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Longitudinal Endpoint Assessment of Disease Burden in HD
RECRUITING
-
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
RECRUITING
-
Extracellular Vesicles for HD
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.